Creative Biolabs provides strain-specific Lactobacillus johnsonii engineering services that connect chassis characterization, construct design, transformation, screening, expression verification, colonization-related phenotyping, genetic stability, safety assessment, and process handoff in one development program. We help engineered-probiotic and mucosal-immunity teams recover qualified candidates while protecting fitness, function, downstream manufacturability, and evidence-package continuity throughout discovery and development.
Lactobacillus johnsonii is a symbiotic bacterium recovered from vaginal, oral, and gastrointestinal niches in vertebrate hosts, including humans, rodents, pigs, and poultry. Its mucosal association, adhesion potential, and capacity to express heterologous proteins make it an attractive research chassis for locally delivered antigens, enzymes, and other functional payloads. This approach can model natural exposure routes in early mucosal research with translational clarity.
That promise comes with a practical constraint: transformation conditions, vector behavior, expression output, and genome-editing efficiency can vary sharply by isolate. Engineering may also reduce growth, colonization-related fitness, or the intended biological response. The intended study context therefore guides assay selection. Creative Biolabs provides an integrated service that connects strain characterization with construct recovery, functional confirmation, stability monitoring, and process-aware candidate selection.
Engineering risk: limited strain-compatible tools can reduce transformation and screening efficiency.
Development risk: a confirmed edit may still compromise payload activity, fitness, stability, or process performance.
We provide modular or end-to-end L. johnsonii engineering services for gene knockout, gene knock-in, gene insertion, and heterologous expression programs. Each work plan is built around the supplied host strain, payload, intended mechanism, and downstream use so that clone recovery is evaluated together with biological performance.
We review strain provenance, available genome information, restriction-modification barriers, antibiotic sensitivity where appropriate, growth requirements, and baseline phenotypes. These data inform a realistic transformation strategy and establish comparators for detecting engineering-related fitness changes.
Our team evaluates promoter logic, copy-number strategy, codon usage, ribosome-binding context, secretion or surface-display signals, selection approach, and integration locus. Designs are matched to constitutive, inducible, intracellular, secreted, or displayed payload requirements.
We construct targeted deletions, insertions, replacements, or complementation strains using a strain-compatible strategy. Screening logic is planned before transformation, with junction or locus confirmation used to distinguish intended clones from background and unresolved intermediates.
Competent-cell preparation, electroporation parameters, recovery conditions, and selection pressure are tuned for the client strain. Candidate colonies progress through staged screening so resources are concentrated on verified, biologically relevant clones.
Sequence confirmation can be paired with PAGE, optional Western blotting, and a client-selected cell-based or biochemical assay. Where the mechanism depends on secretion, surface display, antigen presentation, or enzymatic output, the assay plan is aligned to the intended mode of action.
We compare engineered and parental strains for growth and colonization-related phenotypes, monitor genetic and expression stability across passages, and organize safety-relevant observations. Early process compatibility checks help reveal whether media, fermentation, harvest, or formulation conditions threaten viability or function.
Lactobacilli are studied as oral and mucosal delivery vehicles because they can combine local residence, low intrinsic immunogenicity, and adjuvant-like interactions with the capacity to express foreign proteins. Recombinant lactobacilli expressing antigens have induced antigen-specific IgG and secretory IgA responses in animal research, supporting further exploration of L. johnsonii for mucosal vaccine discovery.
Earlier proof-of-concept work engineered L. johnsonii to produce and secrete CP25L endolysin, which showed in vitro activity against Clostridium perfringens. This illustrates how payload design, secretion, functional testing, and host-strain fitness must be evaluated as one connected development question.
A defined scope keeps the construction campaign, acceptance criteria, and downstream decisions aligned. Final deliverables can be adjusted to the construct type and biological endpoint.
| Project Element | Included Scope | Decision Value |
|---|---|---|
| Services | Gene knockout; gene knock-in or gene insertion; construct optimization; transformation and clone screening. | Generates the intended strain and a documented route from design to recovered clone. |
| Deliverables | Confirmed engineered strain supplied as glycerol stock, with a concise construction and QC summary. | Provides a traceable research material for functional studies and process development. |
| Quality Control | Sequencing validation, PAGE, optional Western blot validation, and a biochemical or cell-based assay of interest when included in scope. | Connects genotype, expression, and intended function rather than relying on colony recovery alone. |
| Estimated Delivery | Starting from 4–6 weeks; final timing depends on host tractability, construct complexity, screening depth, and assay scope. | Sets a realistic schedule around strain-specific technical risk. |
| Materials from Clients | Overall construction scheme, host strain, target gene name, and target gene sequence when a complete genome sequence is unavailable. | Enables rapid feasibility review, construct planning, and project-specific acceptance criteria. |
Our workflow uses early feasibility gates and paired genotype–phenotype checks to keep weak constructs from consuming downstream development time.
Review the host strain, genome availability, target sequence, desired edit, payload location, expected expression mode, and acceptance criteria.
Establish identity, growth behavior, transformation constraints, and the phenotypic baseline needed for later comparability.
Select an appropriate editing or expression architecture, finalize sequence elements, and define screening and fallback strategies.
Optimize competent-cell preparation and recovery, transform the construct, and screen candidate clones with edit-specific assays.
Confirm sequence, expression, payload activity, growth, and colonization-related phenotypes against agreed controls.
Assess passage stability and process-relevant performance, then deliver the glycerol stock and project documentation.
Recently published research constructed recombinant L. johnsonii carrying a GM-CSF expression plasmid and documented the design, target amplification, restriction analysis, clone PCR, passage-related genetic stability, and protein expression within one evidence sequence. The image illustrates why strain construction should be judged through multiple orthogonal checkpoints rather than by antibiotic-resistant colony recovery alone. Together, these readouts make construct identity, expression, and stability visible at the same development checkpoint.
For live biotherapeutic discovery teams, the study is especially relevant because it links vector architecture and electroporation to expression confirmation and retained activity. It also highlights the value of testing genetic stability over successive generations before advancing a candidate. Creative Biolabs can translate this logic into a project-specific package that combines chassis preparation, construct recovery, sequencing, expression analysis, functional assays, fitness comparison, and early process-readiness checks. The resulting evidence supports informed down-selection before broader mucosal or in vivo studies with greater technical confidence.
The chassis offers valuable mucosal and expression properties, while our integrated service keeps construction, function, stability, and downstream feasibility connected.
Extend a qualified L. johnsonii construct into broader strain design, genetic modification, integration-stability, and development-oriented bioprocess programs.
L. johnsonii has a long history in probiotic research and offers strain-dependent potential for pathogen antagonism, immune regulation, inflammation-related studies, metabolic modulation, epithelial-barrier support, and mucosal delivery. Its value as an engineering chassis depends on the specific isolate, intended payload, target site, and evidence generated for fitness and function.
Yes. We support gene knockout, gene insertion, replacement, integration, and complementation projects. The final strategy depends on the host genome, available selection system, target locus, insert size, desired marker status, and strain-specific transformation performance.
Verification can include sequencing, PAGE, optional Western blotting, and a biochemical or cell-based assay selected for the intended payload. We can also compare growth and colonization-related phenotypes with the parental strain to identify performance losses introduced by engineering.
Please provide the overall construction scheme, host strain, target gene name, and target gene sequence if a complete genome sequence is unavailable. Preliminary growth conditions, prior transformation history, and target assay information are also helpful for feasibility planning.
Delivery starts from approximately 4–6 weeks for suitable projects. Timing varies with strain tractability, construct complexity, clone recovery, sequence confirmation, functional-assay scope, and any passage-stability or process-compatibility work included in the project.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.
